As co-author, excited to share CLARITY-Gastric01 data. Sone-Ve showed a meaningful survival benefit for pts with previously treated CLDN18.2-positive GC/GEJ cancers, reinforcing CLDN18.2 as a key therapeutic target beyond the frontline setting. #ESMO2026 #GIOncology